Resource Summary Report

Generated by RRID on Jul 29, 2026

BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1

RRID:AB_395739
Type: Antibody

Proper Citation

BD Biosciences Cat# 555332, RRID:AB_395739

Antibody Information

URL: http://antibodyregistry.org/AB_395739

Proper Citation: BD Biosciences Cat# 555332, RRID:AB_395739

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: UCHT1

Antibody ID: AB_395739

Vendor: BD Biosciences

Catalog Number: 555332

Record Creation Time: 20250820T054603+0000

Record Last Update: 20250820T222441+0000

Ratings and Alerts

No rating or validation information has been found for BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1.

No alerts have been found for BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. Cell reports. Medicine, 6(12), 102466.

Guthmiller JJ, et al. (2025) Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutinins. Immunity, 58(4), 980.

Lin S, et al. (2025) Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. iScience, 28(5), 112497.

Schweihofer V, et al. (2025) Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. Frontiers in oncology, 15, 1622008.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. Immunity, 58(6), 1502.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. Cell reports, 45(1), 116757.

Zhang J, et al. (2024) Pyroptotic T cell-derived active IL-16 has a driving function in ovarian endometriosis development. Cell reports. Medicine, 5(3), 101476.

Bruss C, et al. (2024) Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative - specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. Frontiers in immunology, 15, 1355130.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell, 187(11), 2817.

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell, 187(2), 390.

Gao J, et al. (2024) Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer. iScience, 27(6), 109946.

Valiate BVS, et al. (2024) Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine. iScience, 27(7), 110177.

Huang X, et al. (2024) Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients. Journal of neurochemistry, 168(3), 224.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. International journal of molecular sciences, 25(13).

Luo Q, et al. (2023) Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell reports, 42(5), 112437.

Zhang Y, et al. (2022) Temporal molecular program of human hematopoietic stem and progenitor cells after birth. Developmental cell, 57(24), 2745.

Li SS, et al. (2022) HLA-B?46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. Cell host & microbe, 30(8), 1173.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell reports. Medicine, 3(10), 100783.

Dejnirattisai W, et al. (2021) The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 184(8), 2183.

Abdul-Jawad S, et al. (2021) Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer cell, 39(2), 257.